article thumbnail

Ovagen breakthrough boosts yellow fever vaccine yields

Pharma Times

Dr Catherine Caulfield, CEO of Ovagen said: “What we have developed isn’t incremental, it’s a complete rethink of the vaccine manufacturing process. Our germ free egg platform eliminates bacterial contamination and reduces the need for antibiotics in vaccine production, while delivering significantly higher viral yield.

Vaccines 103
article thumbnail

Osivax publishes phase 2a results supporting dual flu vaccine approach

Pharma Times

The results, now published in Vaccines , show that the combination was well-tolerated with no serious adverse events, and generated strong immune responses. Series A to advance radioligand therapy platform Jul 9, 2025 VarmX secures US approval to begin phase 3 trial of urgent surgery treatment Jul 8, 2025 News alerts This field is required.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Flu Vaccines Are a Go

Pharmacy Times

The shift away from thimerosal may increase the use of single-dose syringes, impacting vaccination practices in various healthcare settings. ACIP's recommendations are increasingly significant for pharmacies, influencing vaccination planning, billing, and patient care activities.

article thumbnail

Moderna flu vaccine shows superior results in phase 3 study

Pharma Times

The vaccine showed a 26.6% higher relative vaccine efficacy compared with the existing option. Across all age groups, risk profiles and vaccination histories, the results were consistently strong. The severity of this past flu season underscores the need for more effective vaccines.” for A/H1N1, 22.2% for B/Victoria.

article thumbnail

Harnessing Marketing Networks in the Pharmaceutical Industry: Strategies for Success

Pharma Marketing Network

To build strong HCP networks: Host webinars and conferences : Share new research and treatment insights. Consider Pfizer’s Science Will Win campaign, which highlighted the companys dedication to vaccine development. Ensure faster adoption of new therapies. Utilize CRM platforms : Track and maintain relationships with physicians.

article thumbnail

Expanding Pneumococcal Vaccinations to Healthy Adults Aged 50 to 64 Years Offers Significant Health, Economic Benefits

Pharmacy Times

Expanding use of the 15-valent pneumococcal conjugate vaccine (PCV15) or 20-valent pneumococcal conjugate vaccine (PCV20) to all United States adults aged 50 to 64 years would result in modest budget increases over a 3-year period.

article thumbnail

COVID-19 Pandemic Reduced Gaps in Pneumococcal Vaccination in Medicare Enrollees, But Lowered Overall Uptake

Pharmacy Times

Increased awareness of infectious diseases during the pandemic may have improved vaccine uptake among Medicare enrollees, while service reductions and vaccine hesitancy affected Medicaid enrollees.